DOI: 10.1155/2023/9919776 ISSN:

Therapeutic Promises of Plant Metabolites against Monkeypox Virus: An In Silico Study

Anik Banik, Sheikh Rashel Ahmed, Sonia Binte Shahid, Tufayel Ahmed, Hafaza Khandaker Tamanna, Hlamrasong Marma
  • Infectious Diseases
  • Virology

The monkeypox virus was still spreading in May 2022, with the first case identified in a person with travel ties to Nigeria. Using molecular docking-based techniques, we evaluated the efficiency of different bioactive chemicals obtained from plants against the monkeypox virus. A total of 56 plant compounds were evaluated for antimonekypox capabilities, with the top four candidates having a higher binding affinity than the control. We targeted the monkeypox profilin-like protein, which plays a key role in viral replication and assembly. Among the metabolites, curcumin showed the strongest binding affinity with a value of −37.43 kcal/mol, followed by gedunin (−34.89 kcal/mol), piperine (−34.58 kcal/mol), and coumadin (−34.14 kcal/mol). Based on ADME and toxicity assessments, the top four substances had no negative impacts. Furthermore, four compounds demonstrated resistance to deformability, which was corroborated by normal mode analysis. According to the bioactivity prediction study, the top compound target class was an enzyme, membrane receptor, and oxidoreductase. Furthermore, the study discovered that wortmannin, a gedunin analogue, can behave as an orthopoxvirus. The study found that these bioactive natural drug candidates could potentially work as monkeypox virus inhibitors. We recommended further experimental validation to confirm the promising findings of the study.

More from our Archive